| LECTURES
|
| Monday,
May 5, 2003 |
| Time |
Title |
Speaker |
|
 |
| 8:00 |
Welcome
and Introduction to the NCI State of the Science Meetings
|
Scott
Saxman, M.D. |
|
| |
Overview
and Charge for the Melanoma SOTS Meeting |
Frank
G. Haluska, M.D., Ph.D.
Vernon K. Sondak, M.D. |
|
|
| SESSION
1: THE PRESENT STATE OF MELANOMA GENETICS
|
|
| 8:15 |
Predisposition
Genetics |
Margaret
Tucker, M.D. |
|
| 8:35 |
RAS
and p16 in Human and Murine Systems |
Lynda
Chin, M.D. |
|
| 8:55 |
BRAF
Mutations in Melanoma and Other Cancers |
Richard
Marais, M.D. |
|
| 9:15 |
Mitf
and bcl-2 |
David
E. Fisher, M.D., Ph.D.
(presentation not available) |
|
| 9:35 |
Commentary |
|
|
| |
|
Pro |
Scott Saxman,
M.D. |
|
| |
|
Con |
Frank Meyskens,
Jr., M.D. |
|
|
| SESSION
2: IDENTIFYING NEW MOLECULAR TARGETS IN MELANOMA |
|
| 10:20 |
High-Throughput
Sequencing and Cancer: Applications to Melanoma |
Paul Meltzer,
M.D., Ph.D. |
|
| 10:40 |
Profiling
Melanomas: Technology and Approaches |
Michael Bittner,
Ph.D. |
|
| 11:00 |
Comparative
Genomic Hybridization |
Boris Bastian,
M.D. |
|
| 11:20 |
Pathology
and Molecular Biology of Melanoma |
David E. Elder,
M.D. |
|
| 11:40 |
Commentary |
|
|
| |
|
Pro |
Jeffrey M. Trent,
Ph.D. |
|
| |
|
Con |
Menashe Bar-Eli,
Ph.D. |
|
|
|
| SESSION
3: IDENTIFICATION OF MINIMAL RESIDUAL DISEASE IN HIGH-RISK
PATIENTS |
|
|
| 1:30 |
The
State of RT-PCR and Sentinel Lymph Node Biopsy |
Douglas S. Reintgen,
M.D. |
|
| 1:50 |
Serum
Markers of Relapse Risk in Melanoma
|
Richard Essner,
M.D. |
|
| 2:10 |
New
Pathology Markers in Melanoma |
Lyn M. Duncan,
M.D. |
|
| 2:30 |
The
Future of Staging and Its Implications for Clinical Trials in Melanoma |
Antonio C. Buzaid,
M.D. |
|
| 2:50 |
Commentary |
|
|
| |
|
Pro |
Kelly M. McMasters,
M.D., Ph.D. |
|
| |
|
Con |
Alexander Eggermont,
M.D., Ph.D. |
|
|
| SESSION
4: THE STATE OF TREATMENT OF METASTATIC DISEASE |
|
|
| 3:35 |
Cytokine
Therapy for Melanoma
|
Michael Atkins,
M.D. |
|
| 3:55 |
Biochemotherapy
in Metastatic Melanoma |
Lawrence Flaherty,
M.D. |
|
| 4:15 |
Immunotherapy
for Melanoma: Future Directions |
Jeffrey S. Weber,
M.D., Ph.D. |
|
| 4:35 |
The
European Perspective for Treatment of Metastatic Melanoma: Implications
for Future Clinical Trials
|
Ulrich Keilholz,
M.D. |
|
| 4:55 |
Gene
and Cellular Therapy for Melanoma
|
James J. Mulé,
Ph.D. |
|
| 2:50 |
Commentary |
|
|
| |
|
Pro |
John M. Kirkwood,
M.D. |
|
| |
|
Con |
Paul B. Chapman,
M.D.
(presentation not available) |
|
|
|
| |
|
|
|
|
| Tuesday,
May 6, 2003 |
| Time |
Title |
Speaker |
|
|
| 6:15 |
Group
Buffet Dinner with Keynote Speaker |
Andrew von Eschenbach,
M.D.
Director, National Cancer Institute |
|
|
| |
|
|
|
|
| Wednesday,
May 7, 2003 |
| Time |
Title |
Speaker |
|
|
| SUMMARY
PRESENTATIONS: PRESENTATION OF RECOMMENDATIONS
BY GROUP LEADERS WITH DISCUSSION BY ENTIRE GROUP |
|
|
| 7:30 |
Working
Group A: Capitalizing on Existing Targets for Therapy
|
|
|
| 8:45 |
Working
Group B: Generating New Targets for the Pipeline
|
|
|
| 10:00 |
Working
Group C: Capitalizing on the Promise of Immunotherapy
|
|
|
| 11:00 |
Working
Group D: Applying Emerging Treatments to High Risk Populations
|
|
|
| 12:00 |
Summary
and Wrap-Up |
Frank G. Haluska,
M.D., Ph.D.
Vernon K. Sondak, M.D.
|
|
